Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Epitalon — also written Epithalon, Epithalone, or AEDG tetrapeptide — is a synthetic four-amino-acid sequence (Ala-Glu-Asp-Gly) modeled on a fragment of epithalamin, a polypeptide extract from bovine pineal gland that the Khavinson lab in Leningrad began characterizing in the 1970s. The synthetic tetrapeptide was designed in 1990 to reproduce what the group described as the "geroprotective" activity of the parent extract in a defined molecule.
It is one of a family of "short peptide bioregulators" the Khavinson lab has published on over more than four decades, alongside Thymalin, Cortexin, Vilon, and several others.
History
The Khavinson group began publishing on pineal extracts and aging in the late 1970s, reporting that long-term administration of epithalamin extended median lifespan in rats and mice. The 1990 synthesis of the AEDG tetrapeptide was an effort to reduce that activity to a defined chemical entity. Through the 1990s and 2000s the lab published a series of papers in Bulletin of Experimental Biology and Medicine and Neuroendocrinology Letters describing telomerase induction in cultured human fibroblasts, extension of replicative lifespan past the Hayflick limit, and reduced age-related mortality in rodent cohorts.
The body of evidence remains heavily concentrated in publications from the originating group. Independent replication of the headline telomerase findings has appeared more recently, including a 2025 Biogerontology paper from a UK group reporting telomere lengthening in human cell lines and a 2025 study showing accelerated bovine oocyte maturation. No Western pharmaceutical company has pursued Epitalon through formal drug development.
Regulatory status
Epitalon is not approved by the FDA, EMA, MHRA, or any other major regulator. Within Russia, peptide bioregulators of this type are sold under a separate regulatory framework as "geroprotectors" and dietary correctors rather than drugs. In the United States, Epitalon is not on the FDA 503A list of bulk substances eligible for compounding and is sold solely through research chemical channels with not-for-human-use labeling.
How researchers describe its action
The mechanism most often cited in the Khavinson papers is direct induction of telomerase activity in somatic cells, with downstream effects attributed to telomere lengthening and shifts in age-related gene expression. The group has also reported binding of the tetrapeptide to specific promoter regions in the human genome, consistent with a transcriptional-modulator hypothesis rather than a classical receptor agonist.
Independent in vitro work has reproduced telomerase induction in cultured human cells, though the magnitude varies between studies. In vivo human pharmacokinetic and target-engagement data remain sparse. None of the proposed mechanisms has been demonstrated in a controlled human clinical trial.
Half-life and dosing intervals
Epitalon has a very short plasma half-life — published estimates fall under 30 minutes after subcutaneous injection, which is typical for small unprotected peptides cleared by serum peptidases. Despite the short exposure, the Khavinson protocols typically use intermittent dosing over short courses rather than continuous administration, on the rationale that downstream transcriptional effects outlast the parent peptide.
In published Russian protocols, common regimens are 5 to 10 mg per day subcutaneously for 10 to 20 days, repeated once or twice yearly. No controlled human dose-finding study has been published in a Western journal. The doses described in observational online use are extrapolated from these Russian protocols, not from regulator-reviewed trials.
Reconstitution example
Epitalon is supplied as a lyophilized powder, most commonly in 10 mg, 20 mg, or 50 mg vials. A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields 5 mg/mL. On a 1 mL U-100 insulin syringe, 20 units (0.2 mL) contains 1 mg. Vial's calculator handles the conversion when vial mass and water volume are entered.
What to know
- Single-lab dominance. The bulk of published efficacy evidence comes from the originating Khavinson group. Independent in vitro replication exists for telomerase induction; human clinical confirmation does not.
- No regulatory approval. Epitalon is not approved by the FDA or any other major regulator. It is not on the FDA 503A compounding list.
- Storage. Lyophilized: refrigerate, protect from light. Reconstituted: refrigerate and use within 2 to 4 weeks per typical short-peptide stability data.
- Safety profile is incomplete. No long-term human safety trial has been published. User reports describe injection-site irritation as the most common observation, but the absence of controlled data means rare or delayed effects are uncharacterized.
- Not the same as epithalamin. The natural pineal extract studied in the original 1970s rodent work is a complex mixture; Epitalon is a single defined tetrapeptide derived from it.
Sources
- 1.Khavinson VKh et al. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine.
- 2.Khavinson VKh et al. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine.
- 3.Araj SK et al. (2025). Overview of Epitalon — Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences.
- 4.Al-Dulaimi S et al. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology.